11 results about "Multiple tumors" patented technology

This invention provides a method for analyzing tumor-specific gene mutations in subjects with multiple tumors, based on gene mutation information identified by ctDNA testing. [Solution] A step of obtaining first gene mutation information identified by ctDNA testing of the subject, second gene mutation information output by analyzing images of a first target area in the subject, and third gene mutation information output by analyzing images of a second target area in the subject that is different from the first target area, and A step of determining whether a tumor-specific gene mutation included in the first gene mutation information is related to a gene mutation in the first target site for imaging included in the second gene mutation information, or a gene mutation in the second target site for imaging included in the third gene mutation information. A method for analyzing gene mutations, comprising the following:

This invention discloses a tumor marker detection system based on an antibody-modified gold nanoparticle periodic linear array, belonging to the field of biomolecular detection. In this invention, a primary antibody is modified onto gold nanowires, and a nanolabel of antibody molecules modified onto gold nanoparticles is prepared as a detection tag (secondary antibody) for tumor markers. A test solution mixed with the secondary antibody is drop-coated onto the structure, and after a sufficient reaction time, the entire structure is rinsed. When light is incident perpendicularly on the gold nanowire array, surface plasmon resonance (SPR) occurs. The tumor markers (antigens) present in the solution are specifically adsorbed with the primary and secondary antibodies, forming a double-antibody sandwich structure, which changes the macroscopic color of the structure. By observing whether the color changes in different regions of the nanowire array after detection, the presence of tumor markers in the test solution can be determined. This invention's system can simultaneously detect multiple tumor markers and features short detection time, small size, low cost, high sensitivity, and ease of outdoor observation.

The application belongs to the field of intelligent medical treatment, and particularly relates to a bladder tumor image segmentation method, device, medium and program product. The method comprises the following steps: S101, acquiring an image of a bladder tumor patient; S102, inputting the image into a 2D U-Net for tumor segmentation to obtain a 2D segmentation result; S103, based on the 2D segmentation result, traversing the shape of the tumor, if the current tumor shape is regular, inputting the image into a 3D U-Net for tumor segmentation to obtain a 3D segmentation result, and taking the segmentation result of the current tumor in the 3D segmentation result; if the tumor shape is irregular, taking the segmentation result of the current tumor in the 2D segmentation result, and after the traversal is completed, merging and outputting the segmentation results of multiple tumors. The application can optimize the segmentation performance by using the complementary advantages of the 2D-3D method, and obtain better segmentation results.

This invention relates to a method for using an antibody-drug conjugate to treat cancer. Specifically, the invention provides a method for using an antibody-drug conjugate, its pharmaceutically acceptable salt, stereoisomer, or metabolite, or a solvate thereof, to treat cancer, and the use of said antibody-drug conjugate in the preparation of medicaments for the prevention and / or treatment of cancer. The method has improved safety and has demonstrated promising antitumor activity in multiple tumor types, meeting medical needs.

This invention discloses an electrochemiluminescence microfluidic chip for the detection of multiple tumor markers, relating to the field of biodetection technology. It includes a substrate and a microfluidic channel system, an electrochemiluminescence detection unit, and a signal acquisition interface integrated on the substrate. The microfluidic channel system includes a sample inlet, a shunt structure, multiple parallel and equally spaced detection channels, and a waste liquid pool connected in sequence. The shunt structure includes a main channel and multiple branch channels integrally formed with the main channel. In this invention, the microfluidic channel system, the electrochemiluminescence detection unit, and the signal acquisition interface are integrated on the same substrate, achieving an integrated design for sample transmission, reaction, detection, and signal export. Compared to traditional distributed detection technologies, this significantly simplifies the detection operation steps, reduces the professional skills required of operators, and shortens the detection cycle, meeting the needs of rapid clinical diagnosis.

A method of delivering tumor treating electric fields to a patient after tumor remission using predictive data in a preventive therapy, which includes the steps of: reviewing a scan of the body; identifying remissive tumor-filled areas on the scan; determining a spatial relationship between remissive tumor-filled areas and predicted locations of tumors; arranging an array of insulated electrode elements on the body, the array of electrode elements being coupled to an electric field generator, a control device configured to send a signal to the generator causing the generator to deliver tumor-preventative electric fields to the electrode elements; determining at least two subarray firing configurations for the array of electrode elements for targeting the remissive tumor-filled areas, the subarray firing configurations depending at least in part upon the spatial relationship between the two remissive tumor-filled areas; and delivering the tumor-treating fields to the remissive tumor-filled areas using the subarray firing configurations.

The invention discloses application of artesunate in preparation of a PRMT1 inhibitor and / or an alpha-ketoglutaric acid supplement, and relates to the technical field of biological medicines. It is found through experiments that artesunate can target and inhibit the activity of arginine methyltransferase of PRMT1, inhibit methylation modification of downstream molecules IDH2 of PRMT1 and reduce expression of the downstream molecules IDH2, and then mitochondrial metabolic disorder in cancer cells is induced, including accumulation of various metabolites such as alpha-ketoglutaric acid. Therefore, a new application of artesunate is provided, and artesunate is used for preparing a PRMT1 inhibitor and / or an alpha-KG supplement. In addition, it is verified that artesunate can significantly inhibit tumor growth of multiple tumor-bearing mice and promote anti-tumor immunity, and artesunate can be used as a PRMT1 inhibitor and / or an alpha-KG supplement to prepare anti-tumor immunotherapy drugs.

This application relates to a method, apparatus, computer device, readable storage medium, and computer program product for processing microscope parameters. The method includes: acquiring input microscope parameters in response to a microscope parameter input operation triggered in a displayed microscope parameter input interface; and displaying a report result display interface in response to a microscope parameter calculation operation triggered in the microscope parameter input interface. The report result display interface includes report results for the number of target fields of view corresponding to multiple different types of tumors. The number of target fields of view is the number of nuclear divisions required to observe each type of tumor within the field of view of a target microscope, based on diagnostic criteria for each type of tumor. The target microscope is the microscope corresponding to the microscope parameters. This method can improve the conversion efficiency between microscope field of view and multiple tumor diagnostic criteria.

The application discloses a prediction model for simultaneously detecting multiple tumors and performing tissue tracing as well as a training method and application thereof, and relates to the technical field of biological medicine. It is found that nucleosome distribution, fragment size distribution, terminal sequence distribution, genomic instability, gene expression prediction and somatic copy number variation can be used as markers to identify whether a sample to be detected contains any one or more of liver cancer, intestinal cancer, esophageal cancer, pancreatic cancer, lung cancer, gastric cancer, ovarian cancer and nasopharyngeal cancer, and to perform tissue tracing. The application has the advantages of high detection sensitivity, good specificity, high tissue tracing accuracy and low detection cost.

The present disclosure describes a machine learning (ML) framework including a graph convolutional neural network (GCN) for identifying gene expression features associated with cancer driven events. The model is trained to identify the TP53 mutation status of a cancer sample from gene expression using a comprehensive selected gene interaction map structure. A quantitative score is generated to rank the severity of the drive events in each sample. By means of the method, an extremely high AUC result is achieved on unseen data of multiple tumor types. And the gene has strong correlation with protein functions. Based on the annotations established in the literature, a transcriptome feature (STAMP) model associated with the mutant protein can also predict driving events of a variety of important cancer gene / pathway combinations and a variety of tumor types. Therefore, the STAMP model can identify and quantify driving events, which can provide a new way for cancer patients to improve selection and priority ranking of targeted therapy.